346 related articles for article (PubMed ID: 8420302)
21. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase.
Xiao-Jun H; Lan-Ping X; Kai-Yan L; Dai-Hong L; Huan C; Wei H; Yu-Hong C; Jing-Zhi W; Yao C; Xiao-Hui Z; Hong-Xia S; Dao-Pei L
Ann Med; 2008; 40(6):444-55. PubMed ID: 18608121
[TBL] [Abstract][Full Text] [Related]
22. Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.
Olsson-Strömberg U; Aleskog A; Björnberg A; Höglund M; Simonsson B; Bengtsson M; Barbany G; Larsson R; Lindhagen E
Anticancer Drugs; 2006 Jul; 17(6):631-9. PubMed ID: 16917208
[TBL] [Abstract][Full Text] [Related]
23. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
[TBL] [Abstract][Full Text] [Related]
24. [Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia].
Liu XL; Zhou SY; Du QF; Zheng WY; Zhang S; Song LL; Xu B; Liu QF; Meng FY
Ai Zheng; 2004 Apr; 23(4):421-5. PubMed ID: 15087031
[TBL] [Abstract][Full Text] [Related]
25. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: prognostic significance of the dose of CD3(+) and CD4(+) lymphocytes.
Vela-Ojeda J; García-Ruiz Esparza MA; Reyes-Maldonado E; Jiménez-Zamudio L; Moreno-Lafont M; García-Latorre E; Ramírez-Sanjuan E; Montiel-Cervantes L; Tripp-Villanueva F; García-León LD; Ayala-Sánchez M; Rosas-Cabral A; Aviña-Zubieta JA; Galindo-Rodríguez G; Vadillo-Buenfil M; Salazar-Exaire D
Ann Hematol; 2004 May; 83(5):295-301. PubMed ID: 15060749
[TBL] [Abstract][Full Text] [Related]
26. Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase.
Kantarjian HM; Shan J; Smith T; Talpaz M; Kozuch P; Rios MB; Cortes J; Giles FJ; O'Brien S
Cancer; 2001 Nov; 92(10):2501-7. PubMed ID: 11745182
[TBL] [Abstract][Full Text] [Related]
27. [Chronic leukemia].
Shibata A; Narita M
Gan To Kagaku Ryoho; 1989 May; 16(5):1982-8. PubMed ID: 2658837
[TBL] [Abstract][Full Text] [Related]
28. [Multivariate analysis of prognostic factors influencing survival in chronic myelogenous leukemia].
Sakamoto S; Kurata H; Miwa A
Rinsho Ketsueki; 1989 Aug; 30(8):1180-4. PubMed ID: 2601030
[TBL] [Abstract][Full Text] [Related]
29. [Undifferentiated blastic cell crisis of chronic myelogenous leukemia with myeloblastic tumor in the skin].
Kawakami K; Kiyosaki M; Amaya H; Nakamaki T; Hino K; Tomoyasu S
Rinsho Ketsueki; 2000 Apr; 41(4):334-40. PubMed ID: 10846465
[TBL] [Abstract][Full Text] [Related]
30. [Detection and quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia by real-time quantitative reverse transcriptase polymerase chain reaction].
Xing W; Gu BW; Zhu YM; Jiang CL; Zhao RH; Wang AH; Sun HP; Li JM; Shen ZX; Chen Z; Chen SJ
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):453-7. PubMed ID: 15854550
[TBL] [Abstract][Full Text] [Related]
31. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
32. Chronic granulocytic leukemia in blastic crisis. Prognostic factors.
Sales V; Rojo J; Collazo J; Lagunas E; Aguilar E; Albisua L
In Vivo; 1991; 5(3):281-5. PubMed ID: 1893082
[TBL] [Abstract][Full Text] [Related]
33. Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy.
Alimena G; Breccia M; Latagliata R; Carmosino I; Russo E; Biondo F; Diverio D; Mancini M; Nanni M; Mandelli F
Cancer; 2006 Sep; 107(5):1008-13. PubMed ID: 16878324
[TBL] [Abstract][Full Text] [Related]
34. Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy.
Atallah E; Talpaz M; O'brien S; Rios MB; Guo JQ; Arlinghaus R; Fernandes-Reese S; Kantarjian H
Cancer; 2002 Jun; 94(11):2996-9. PubMed ID: 12115389
[TBL] [Abstract][Full Text] [Related]
35. [The efficacy of imatinib mesylate for 124 patients with chronic myeloid leukemia in accelerated and blastic phase].
Jiang Q; Chen SS; Jiang B; Jiang H; Qiu JY; Liu YR; Zhang Y; Qin YQ; Lu Y; Huang XJ; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2007 Nov; 28(11):721-6. PubMed ID: 18457260
[TBL] [Abstract][Full Text] [Related]
36. [Allogeneic bone marrow transplantation in chronic myeloid leukemia. The clinical results and risk factors in 70 patients].
Tomás JF; Peñarrubia MJ; García JA; Figuera A; Gómez-García de Soria V; Steegmann JL; Arranz R; Cámara R; Gabriel R; Vázquez L
Med Clin (Barc); 1995 Nov; 105(16):605-11. PubMed ID: 8523939
[TBL] [Abstract][Full Text] [Related]
37. Immunological classification of chronic myeloid leukemia distinguishes chronic phase, imminent blastic transformation, and acute lymphoblastic leukemia.
Schmetzer HM; Gerhartz HH
Exp Hematol; 1997 Jun; 25(6):502-8. PubMed ID: 9197328
[TBL] [Abstract][Full Text] [Related]
38. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
39. Lymphoid blast crisis during interferon-alpha therapy in a patient with chronic myelogenous leukemia in myeloid blast crisis.
Goto H; Tsurumi H; Hara T; Moriwaki H
Int J Hematol; 2000 Dec; 72(4):474-6. PubMed ID: 11197215
[TBL] [Abstract][Full Text] [Related]
40. Monitoring treatment and survival in chronic myeloid leukemia. Italian Cooperative Study Group on Chronic Myeloid Leukemia and Italian Group for Bone Marrow Transplantation.
J Clin Oncol; 1999 Jun; 17(6):1858-68. PubMed ID: 10561226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
